Geulah Livshits
Stock Analyst at Chardan Capital
(1.86)
# 2,971
Out of 4,826 analysts
187
Total ratings
27.22%
Success rate
-8.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMRX Immuneering | Maintains: Buy | $13 | $1.25 | +940.00% | 11 | May 6, 2025 | |
| SNTI Senti Biosciences | Maintains: Buy | $12 | $3.28 | +265.85% | 8 | May 2, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $50 | $23.86 | +109.56% | 1 | Apr 9, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Buy | $25 → $22 | $4.45 | +394.38% | 8 | Apr 8, 2025 | |
| IPSC Century Therapeutics | Maintains: Buy | $11 → $7 | $0.56 | +1,147.55% | 5 | Mar 24, 2025 | |
| PRME Prime Medicine | Maintains: Buy | $15 → $16 | $1.57 | +919.11% | 4 | Mar 20, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $18 → $9 | $0.50 | +1,708.32% | 10 | Mar 12, 2025 | |
| SLDB Solid Biosciences | Maintains: Buy | $16 | $4.23 | +278.25% | 6 | Mar 7, 2025 | |
| PASG Passage Bio | Maintains: Buy | $7 → $6 | $0.36 | +1,574.11% | 4 | Mar 4, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $30 → $28 | $3.57 | +684.31% | 8 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $30 | $3.50 | +757.14% | 11 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 → $54 | $7.85 | +587.90% | 15 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $91 → $68 | $8.44 | +705.69% | 13 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 | $2.46 | +185.13% | 12 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $212 → $218 | $162.29 | +34.33% | 9 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $94 → $84 | $37.62 | +123.29% | 12 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.24 | - | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.54 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 | $1.57 | +855.41% | 5 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $6.44 | +537.14% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $25 | $5.10 | +390.20% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.28 | +837.50% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $27.84 | +647.13% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.31 | +1,121.37% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $2.5 | $6.95 | -64.03% | 5 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $9.76 | +822.13% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.49 | +14.61% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $3.58 | +737.99% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $8.50 | +111.76% | 1 | Oct 27, 2020 |
Immuneering
May 6, 2025
Maintains: Buy
Price Target: $13
Current: $1.25
Upside: +940.00%
Senti Biosciences
May 2, 2025
Maintains: Buy
Price Target: $12
Current: $3.28
Upside: +265.85%
Palvella Therapeutics
Apr 9, 2025
Initiates: Buy
Price Target: $50
Current: $23.86
Upside: +109.56%
Lexeo Therapeutics
Apr 8, 2025
Maintains: Buy
Price Target: $25 → $22
Current: $4.45
Upside: +394.38%
Century Therapeutics
Mar 24, 2025
Maintains: Buy
Price Target: $11 → $7
Current: $0.56
Upside: +1,147.55%
Prime Medicine
Mar 20, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $1.57
Upside: +919.11%
Tenaya Therapeutics
Mar 12, 2025
Maintains: Buy
Price Target: $18 → $9
Current: $0.50
Upside: +1,708.32%
Solid Biosciences
Mar 7, 2025
Maintains: Buy
Price Target: $16
Current: $4.23
Upside: +278.25%
Passage Bio
Mar 4, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.36
Upside: +1,574.11%
4D Molecular Therapeutics
Mar 4, 2025
Maintains: Buy
Price Target: $30 → $28
Current: $3.57
Upside: +684.31%
Mar 3, 2025
Maintains: Buy
Price Target: $34 → $30
Current: $3.50
Upside: +757.14%
Feb 28, 2025
Maintains: Buy
Price Target: $62 → $54
Current: $7.85
Upside: +587.90%
Feb 28, 2025
Maintains: Buy
Price Target: $91 → $68
Current: $8.44
Upside: +705.69%
Feb 26, 2025
Maintains: Buy
Price Target: $7
Current: $2.46
Upside: +185.13%
Feb 20, 2025
Maintains: Buy
Price Target: $212 → $218
Current: $162.29
Upside: +34.33%
Feb 13, 2025
Maintains: Buy
Price Target: $94 → $84
Current: $37.62
Upside: +123.29%
Jan 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.24
Upside: -
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.54
Upside: -
Nov 20, 2024
Maintains: Buy
Price Target: $15
Current: $1.57
Upside: +855.41%
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $6.44
Upside: +537.14%
Mar 23, 2023
Maintains: Buy
Price Target: $28 → $25
Current: $5.10
Upside: +390.20%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $1.28
Upside: +837.50%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $27.84
Upside: +647.13%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $1.31
Upside: +1,121.37%
Aug 22, 2022
Maintains: Buy
Price Target: $4 → $2.5
Current: $6.95
Upside: -64.03%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $9.76
Upside: +822.13%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.49
Upside: +14.61%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $3.58
Upside: +737.99%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $8.50
Upside: +111.76%